Filing identity and reporting period
The supplied filing is MEI Pharma, Inc.’s Form 10-Q for the quarter ended March 31, 2017 (the third quarter of fiscal 2017), filed May 3, 2017. This conflicts with the request metadata, which identifies Lite Strategy, Inc. and 2015 Q3; the filing text does not support that metadata.
Business context
MEI Pharma is a clinical-stage oncology company. Its portfolio includes Pracinostat, licensed worldwide to Helsinn for development and commercialization, and ME-401 and ME-344, which MEI continues to develop.
Financial results and liquidity
Amounts below are in millions of dollars unless noted. Balance-sheet comparisons are March 31, 2017 versus June 30, 2016; income and cash-flow comparisons are for the nine months ended March 31.
| Metric | Current period / date | Prior comparable |
|---|---|---|
| Revenue | $22.8 for nine months; $4.5 for the quarter | No revenue in 2016 periods |
| Net income (loss) | $7.0 for nine months; $(0.6) for the quarter | $(15.1) for nine months; $(5.4) for the quarter |
| Basic and diluted EPS | $0.19 for nine months; $(0.02) for the quarter | $(0.44) and $(0.16), respectively |
| Operating cash flow | $6.6 for nine months | $(14.4) |
| Cash, equivalents and short-term investments | $56.8 | $45.9 |
| Total assets | $59.9 | $47.2 |
| Current liabilities | $5.0 | $5.5 |
| Stockholders’ equity | $54.9 | $41.7 |
MEI reported no long-term debt on the presented balance sheet. Short-term investments were $45.1 million, consisting of U.S. government securities. Management said available cash and investments were expected to fund operations through at least calendar year 2018. No operating margin is stated; reported operating income for the nine-month period was $6.8 million, versus an operating loss of $15.2 million in 2016.
Material changes and drivers
- Nine-month revenue included $20.9 million of Pracinostat license revenue and $1.9 million of research and development revenue under the Helsinn agreement. The comparable 2016 period had none.
- The quarter’s license revenue was $3.8 million, with $0.7 million of research and development revenue. License revenue reflects recognition of allocated agreement consideration as performance obligations were completed; it should not be read as equivalent to cash received in the period.
- Nine-month R&D expense fell to $5.2 million from $9.4 million, mainly because Helsinn assumed primary responsibility for Pracinostat development funding and clinical costs declined. The company also cited a $1.9 million reduction from revised estimates of amounts owed to trial contractors for nearly completed studies.
- G&A expense rose to $6.8 million from $5.8 million, primarily due to professional services related to the Helsinn agreement. Nine-month operating cash flow benefited from the agreement’s $20 million in upfront payments.
- Investing activity used $10.0 million net, primarily reflecting purchases of short-term investments exceeding maturities. Financing provided $4.2 million, associated with Helsinn’s equity investment. Shares outstanding at March 31 were 36.8 million, compared with 34.2 million at June 30, 2016.
Outlook, risks and contingencies
- Helsinn is primarily responsible for funding Pracinostat’s global development and commercialization. MEI remains eligible for up to $444 million in regulatory and sales milestones plus royalties, but these amounts are contingent and not assured.
- MEI expected enrollment in a shared-cost Phase II Pracinostat study for high- and very-high-risk MDS to begin in the second quarter of calendar 2017. Interim ME-401 data were expected in June 2017 and interim ME-344 study data in December 2017.
- Management expected operating losses and negative operating cash flows for the foreseeable future and said future development may require additional financing or strategic transactions. It concluded there was no going-concern issue.
- Key risks include clinical trial failure or delay, regulatory uncertainty, reliance on collaborators and licensees, financing needs, manufacturing costs, competition, and intellectual-property risks. The filing reported no material change to previously disclosed risk factors and no legal proceedings.
- Potential obligations include up to $75.2 million of S*Bio clinical, regulatory and sales milestones; $0.7 million was accrued for potential future payments. The office lease transitions from approximately $29,000 monthly through June 2017 to a new lease at approximately $44,000 monthly from July 2017 through May 2020.
- The company reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the issuer and period: the filing is MEI Pharma’s March 31, 2017 Form 10-Q, not a Lite Strategy 2015 Q3 filing.
- Review the accounting and timing behind the $22.8 million of nine-month revenue, including license-fee allocation, remaining Helsinn performance obligations, and cash receipts.
- Assess cash runway against clinical spending, shared study costs, lease commitments, and management’s stated expectation of possible future financing.
- Track the clinical milestones and results for Pracinostat, ME-401 and ME-344, as well as Helsinn’s development and funding performance.
- Consider contingent S*Bio payments and potential dilution: the filing disclosed 8.1 million potentially dilutive shares excluded from quarterly diluted EPS and outstanding warrants to purchase approximately 3.5 million shares.